What is the appropriate management for a patient with acute hepatitis B presenting with a total bilirubin of 14 mg/dL and ALT of 2500 IU/L?

Immediate Antiviral Treatment Required

For a patient with acute hepatitis B presenting with bilirubin 14 mg/dL and ALT 2500 IU/L, immediate antiviral therapy with a potent nucleos(t)ide analogue (entecavir or tenofovir) should be initiated without delay. This represents severe acute hepatitis B with significant risk of progression to liver failure and death.

Clinical Severity Assessment

This patient meets criteria for severe acute hepatitis B based on:

• Bilirubin >10 mg/dL (14 mg/dL indicates significant hepatocellular injury)
• Markedly elevated ALT (2500 IU/L demonstrates severe hepatocyte lysis)
• Presence of jaundice (icteric presentation)

The 2007 AASLD guidelines explicitly state: "Immediate treatment if icteric or clinical decompensation" 1. This patient's bilirubin of 14 mg/dL clearly qualifies as icteric presentation requiring urgent intervention.

Evidence for Immediate Treatment

Multiple studies demonstrate that prompt antiviral therapy in severe acute hepatitis B significantly improves survival (approximately 80% survival with treatment vs. considerably poor outcomes without) 2. Critically, patients who died or required transplantation despite lamivudine therapy were those who started treatment at advanced stages compared to survivors 2. Timing is crucial—delayed treatment reduces efficacy.

A pilot study of 15 patients with severe acute HBV (mean bilirubin 18 mg/dL, similar to this case) showed that lamivudine prevented progression to fulminant hepatitis in 86.6% of patients, with encephalopathy disappearing within 3 days and coagulopathy improving within 1 week 3. The two patients who progressed to fulminant hepatitis requiring transplantation were those in whom lamivudine was delayed 3.

Recommended Treatment Regimen

First-line agent: Entecavir 0.5 mg daily OR Tenofovir (DF 245 mg or AF) daily

While most published studies used lamivudine 4, 2, 3, 5, current guidelines recommend more potent antivirals with higher genetic barriers to resistance 6, 7, 8. The 2020 KASL guidelines specify entecavir, tenofovir DF, or tenofovir AF as first-line agents for decompensated cirrhosis 6, and this principle applies to severe acute presentations.

Rationale for choosing entecavir/tenofovir over lamivudine:

• Higher potency for rapid viral suppression
• Lower resistance rates (1.2% at 5 years for entecavir vs. high rates for lamivudine) 9
• Better long-term outcomes 7
• In severe presentations, you cannot afford treatment failure from resistance

Critical Management Points

Do NOT delay treatment for:

• Liver biopsy
• Additional testing beyond confirming HBsAg positivity
• Observation period (the 3-6 month observation window applies only to compensated patients with ALT >2× ULN, NOT icteric patients) 1

Immediate actions:

1. Start antiviral therapy today (within hours, not days)
2. Check baseline HBV DNA, HBeAg status, complete metabolic panel, PT/INR
3. Assess for signs of hepatic decompensation (encephalopathy, coagulopathy, ascites)
4. Coordinate with transplant center immediately if any signs of decompensation present 1

Monitoring during acute phase:

• Daily assessment of mental status and coagulopathy
• ALT, bilirubin, INR every 2-3 days initially
• Watch for progression despite treatment (rising bilirubin, worsening coagulopathy, encephalopathy)

Prognosis and Treatment Duration

With prompt treatment, expect:

• Clinical improvement within 3-7 days (resolution of encephalopathy if present, improvement in coagulopathy) 3
• Bilirubin decline starting within 1-2 weeks
• HBV DNA undetectable within 4 weeks 3
• ALT normalization within 8 weeks 3

Treatment duration: Continue antiviral therapy for at least 3-6 months after clinical and biochemical resolution 3, 5. Monitor for HBeAg seroconversion if initially HBeAg-positive. Some patients may achieve HBsAg clearance and can discontinue therapy; others may require longer treatment.

Common Pitfall to Avoid

The most critical error is delaying treatment while "observing" the patient. The 2007 AASLD guideline's recommendation to "observe for 3-6 months" applies ONLY to compensated HBeAg-positive patients with ALT >2× ULN who might achieve spontaneous HBeAg seroconversion 1. This does NOT apply to icteric patients with bilirubin 14 mg/dL—such patients require immediate treatment to prevent progression to fulminant hepatic failure.

Transplant Evaluation

Given the severity (bilirubin 14 mg/dL), contact your regional transplant center now for evaluation, even as you initiate antiviral therapy 1. If the patient develops worsening coagulopathy (INR >2.5), encephalopathy, or rising bilirubin despite treatment, urgent liver transplantation may be life-saving. Antiviral therapy may prevent this progression, but you must be prepared.